Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 24

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 24
---
, the TuHURA Charter and the TuHURA Bylaws. For more information regarding the principal effects of the Delaware Conversion, see “TuHURA Proposal 2: Approval of the Delaware Conversion.”                                      |

For more information regarding the Merger Consideration to be received by Kineta stockholders if the Mergers are completed, see “The Merger Agreement—Merger Consideration.” If the Mergers are completed, Kineta will no longer be a public company, will deregister under the Exchange Act, and will cease to be traded on the OTC. 12

| Q: | What will the holders of Kineta stock options receive in the Mergers? |

A: At the Effective Time:

| • |     | each In-the-Money Company Stock                                                                                                                                        
 Option that is vested or unvested and held by a Person will be entitled to exercise such In-the-Money Company Stock Option as set forth in the applicable Optionholder 
 Treatment Agreement and, upon such exercise, will be entitled to receive the Merger Consideration;                                                                     |

| • |     | each                                                                                                           
 Out-of-the-Money Company Stock Option held by a Person will be canceled and extinguished for no consideration; |

| • |     | the Pre-2023 Company Warrants will terminate upon their terms if such Pre-2023 Company Warrants are not previously exercised (if the Pre-2023 Company Warrants are exercised prior to the Effective Time, as a holder of shares of Kineta Common 
 Stock, the holder of such former Pre-2023 Company Warrants will be entitled to receive the Merger Consideration); and                                                                                                                            |

| • |     | the 2023 Company Warrants will be entitled to the benefits as set forth in the applicable Warrantholder Treatment 
 Agreement.                                                                                                        |

On March 7, 2025, Kineta entered into a securities exchange agreement (the “Exchange Agreement”) with an existing investor and holder of some of the 2023 Company Warrants (the “Holder”) pursuant to which Kineta agreed to issue an aggregate of 1,880,342 shares of Kineta Common Stock consisting of (i) an aggregate of 1,225,323 shares of Kineta Common Stock and (ii) a pre-funded warrant to purchase up to an aggregate of 655,019 shares of Kineta Common Stock, in exchange for certain outstanding 2023 Company Warrants (the “Prior Warrants”) held by the Holder to purchase up to